CRISPR Therapeutics AG — Director's Dealing 2018

Mar 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-03-07

Reporting Person: Ho Tony W (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-07	Stock Option (Right to Buy)	$51.49	A	53000	Acquired	2028-03-07	Common Shares (53000)	Direct

Footnotes

F1: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments.